5 results about "Hydroxypropyl-beta-cyclodextrin" patented technology

The invention belongs to the field of medical instrument coloring agents, and provides a natural anthocyanin endoscope coloring agent. According to the invention, the innovative design of combining a ternary color-stabilizing compound formed by anthocyanin, a co-chromophore and hydroxypropyl beta cyclodextrin with a chitosan sodium alginate polysaccharide system and a composite buffer system is adopted, and the viscosity is controlled to be 200-320 millisecond, the particle size of spray droplets is 40-60 microns, and the thickness of a thin film is 10-30 microns through specific molar ratio compatibility and a genipin crosslinking technology. Through accurate regulation and control, the excellent performance that a double-network thin layer is formed under the calcium ion environment that the absorbance retention rate at 520 nanometers is not lower than 90% and the elution rate is not lower than 90% under the irradiation of hundred thousand lux white light is achieved, the technical problems that a traditional endoscope coloring agent is poor in safety, low in stability and insufficient in mucous membrane contrast ratio are solved, and the wide clinical application value is achieved.

Described herein are clear, stable aqueous formulations comprising—in relevant part—leucovorin calcium; substituted cyclodextrins, specifically betadex suclfobutyl ether cyclodextrin (SBE-β-CD) or hydroxypropyl beta cyclodextrin (HP-β-CD), designed for parenteral administration. The formulations are designed to effectively prevent drug crystallization and particulate matter formation, addressing major stability challenges associated with existing products. These advancements not only improve the safety and efficacy of leucovorin calcium for intravenous administration but also facilitate compliance with regulatory standards, providing a reliable therapeutic option for patients. Methods of making and using these formulations are also described herein.

The invention discloses salicylic acid sustained-release microspheres prepared by a cyclodextrin inclusion technology and a preparation method of the salicylic acid sustained-release microspheres, and belongs to the technical field of pharmaceutical preparations. The method aims to solve the problems of poor solubility, low drug loading capacity and lack of sustained-release capability of traditional cyclodextrin inclusion salicylic acid. The core of the method is that two brand new functional compounds, namely quaternary ammonium salt hydroxypropyl beta cyclodextrin and nicotinamide poloxamer covalent conjugates, are firstly prepared; when the microspheres are prepared, the two compounds are dissolved in a mixed solvent of ethanol and water, then salicylic acid and nicotinamide are added, a supramolecular inclusion solution is formed through stirring, and finally a microsphere product is obtained through spray drying and screening. Wherein the affinity with the skin is enhanced by the cationic cyclodextrin derivative, the nicotinamide conjugate and salicylic acid form a stable compound through intermolecular interaction, and efficient inclusion and loading of salicylic acid are realized through synergism of the cationic cyclodextrin derivative and the nicotinamide conjugate. The dissolvability, the solution transparency and the storage stability of salicylic acid are remarkably improved, the microsphere wrapping amount is high, a good slow-release effect is achieved, and the salicylic acid microsphere is suitable for the field of skin external preparations.

The invention discloses a preparation method of cationic polyacrylamide for an oil field in the field of oilfield chemical agents, which comprises the following steps: firstly, preparing a carbon dioxide response type star polymer modified material which is synthesized by taking ethylenediamine as a core through four-step reaction: firstly, reacting with a brominating reagent to form a four-arm initiator; carrying out atom transfer radical polymerization on the star-shaped polymer, dimethylaminoethyl acrylate and hexafluorobutyl acrylate to construct a star-shaped skeleton; then carrying out inclusion modification with hydroxypropyl beta cyclodextrin through host-guest interaction; and finally, performing double crosslinking through zinc ion coordination and etherification reaction to obtain the modified material. The modified material, acrylamide, a cationic monomer and an auxiliary monomer are dissolved in water, a two-stage polymerization process of low-temperature pre-polymerization and high-temperature post-polymerization is performed, and granulation, drying and crushing are performed to obtain a final product. The polyacrylamide prepared by the method shows excellent tackifying performance and temperature-resistant and salt-resistant performance in oil field application, and is especially suitable for tertiary oil recovery operation under high-temperature and high-salt oil reservoir conditions.

The present invention relates to a stable aqueous formulation of Leucovorin calcium designed for parenteral administration. This formulation utilizes substituted cyclodextrins, specifically Betadex sulfobutyl ether cyclodextrin (SBE-β-CD) or Hydroxypropyl Beta Cyclodextrin (HP-β-CD), as solubilizers and stabilizers to enhance the drug's aqueous solubility. The inclusion of Tromethamine serves as a buffering agent, maintaining optimal pH levels and ensuring the chemical stability of Leucovorin over an extended shelf life. Importantly, the formulation effectively prevents drug crystallization and particulate matter formation, addressing major stability challenges associated with existing products. The formulation's resilience to freeze-thaw cycles confirm its physical and chemical stability under stress conditions. These advancements not only improve the safety and efficacy of Leucovorin calcium for intravenous administration but also facilitate compliance with regulatory standards, providing a reliable therapeutic option for patients.